News
Pharmaceutical
In a filing with the US Securities and Exchange Commission (SEC), Californian biotech Alumis has revealed it aims to raise around $300 million in its upcoming initial public offering (IPO). 25 June 2024
Today's issue
Refine Search
Pharmaceutical
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued recommendations to tackle shortages of glucagon-like peptide-1 (GLP-1) receptor agonists. 26 June 2024
Biotechnology
US RNA specialist Wave Life Sciences has presented positive results from its Phase Ib/IIa SELECT-HD trial of WVE-003, which is being developed as a potential disease modifying therapeutic for Huntington’s disease (HD). 26 June 2024
Pharmaceutical
Braeburn (Nasdaq: BBRX) has published a post hoc analysis of data from a Phase III trial of Brixadi (buprenorphine) in the Journal of the American Medical Association (JAMA). 26 June 2024
Pharmaceutical
Danish drugmaker Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) has been approved in China for long-term weight management. 26 June 2024
Pharmaceutical
NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotechnology company focused on cardiometabolic diseases, has raised around $70 million through a private share placement. 26 June 2024
Biotechnology
Mixed results for AstraZeneca's (LSE: AZN) Imfinzi (durvalumab) have been reported, with success in bladder cancer and a late-stage miss in lung cancer. 26 June 2024
Pharmaceutical
London-based pharma major GSK—one of the UK’s flagship companies—has suffered a galling defeat on home soil to US rival Pfizer. 25 June 2024
Biotechnology
French biotech MaaT Pharma has appointed Gianfranco Pittari as chief medical officer. 25 June 2024
Biotechnology
German pharma major Bayer’s BAY2927088 recently received the Breakthrough Therapy designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. 25 June 2024
Biotechnology
This week we’re focusing on MASH. It’s a high area of unmet medical need, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development. 25 June 2024
Pharmaceutical
Russia will speed up the process of launching generics of original drugs that have been withdrawn from the market by their producers in a move to ensure better security of the country in its pharmaceutical sector, reports The Pharma Letter’s local correspondent. 25 June 2024